| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.008 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.099 | 0.02 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |